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Abstract
Background: The TITRATE trial seeks to test whether intensive management is valuable in achieving disease remission in
moderately active rheumatoid arthritis. Intensive management is a complex intervention consisting of: 1) 12 x monthly
appointments, 2) tailored ‘treatment support’ based on motivational interviewing techniques, 3) optimised medication
(including the opportunity for biologics), 4) provision of a Patient Handbook, and 5) shared treatment planning. This study
aims to understand: a) patients’ and practitioners’ views on the feasibility and acceptability of intensive management, and
b) patients’ and practitioners’ experience of receiving/providing intensive management.
Methods: A qualitative study, nested within a randomised controlled trial. Participants were patients (n = 15) in the
intensive management arm of the trial and rheumatology practitioners (n = 16) providing the intensive management
intervention, from 18/42 clinics across England. Data were collected via semi-structured interviews and analysed using
thematic analysis and iterative categorization.
Results: Monthly appointments were largely acceptable to both groups who cited several treatment benefits (e.g. regular
review of medication, practitioners built close relationships with patients). Practitioners were ‘fairly confident’ using the
motivational interviewing techniques. Learning to pace was the most commonly reported self-management technique
that patients and healthcare professionals worked on together, followed by gaining control over pain and fatigue.
Practitioners liked having the option to offer biologics to patients with moderate RA. Most patients found the optimised
medication (following monthly joint assessment) helpful and side-effects experienced were resolved. Variation existed in
the extent to which patients engaged with the Patient Handbook and shared treatment planning, with those who did
engage doing so in the early stages.
Conclusions: Feedback from patient participants about the intensive management intervention was positive. They found
increased medication helpful. Continuity of care with the same healthcare professional at regular intensive management
sessions, and the treatment support provided, were highly rated. Feedback from practitioners indicated that intensive
management training is feasible. Evidence from the interviews showed that some practitioners applied motivational
interviewing techniques during standard care appointments and they would like the opportunity to address lifestyle
issues with patients.
Keywords: Acceptability, Complex intervention, Feasibility, Intensive management, Motivational interviewing,
Practitioners, Qualitative, Rheumatoid arthritis
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Background
Rheumatoid arthritis (RA) is a chronic autoimmune inflam-
matory joint disease, which can cause cartilage and bone
damage as well as disability [1]. The main physical symp-
toms are pain, fatigue, stiffness and swelling of the joints
[2]. Patients also experience psycho-social consequences,
including social isolation and depression [3, 4].
Patients with RA are sub-divided by their disease ac-
tivity levels; assessed by the disease activity score for 28
joints (DAS28) with scores which range from 0 to 9 [5].
Treatment choices for RA often depend on disease activ-
ity (as measured by the DAS28). Many patients that
attend rheumatology clinics have ‘moderate’ disease ac-
tivity [6] (DAS28 3.2–5.1). This means they have
achieved some degree of disease control but are not in
remission (DAS28 < 2.6).
Biologic therapies were first studied in patients with
active disease (DAS28 > 5.1). The National Institute for
Health and Care Excellence (NICE) [7] restrict the use
of biologic therapies in moderate disease patients; even
though evidence indicates that they are effective in less
severe disease states [8]. Currently, recommendations for
the management of patients with moderate disease activity
are treatment with disease-modifying anti-rheumatic
drugs (DMARDs) and steroids, and an annual specialist
review [7].
There is some evidence which suggests that patients
with moderate RA would try intensive management. A
qualitative study [9] examined the views and expecta-
tions of patients with moderate RA about intensive man-
agement strategies. Monthly appointments were largely
acceptable to patients, who focused on a desire to im-
prove their physical symptoms, namely reduced pain
and better mobility. Patients who did not think that their
treatment controlled their RA were more likely to try in-
tensive management. Some, however, expressed con-
cerns about taking higher doses of medication because
of the potential side-effects. There was significant het-
erogeneity in patients’ interest in educational materials.
These findings were supported by earlier qualitative
studies [10, 11] which investigated the experiences of pa-
tients with active RA who were in receipt of biologics.
Several studies have examined the impact clinicians’
support has on patients with RA. A recent systematic re-
view [12] found that higher levels of trust in the clinician
and active patient participation in the medical consult-
ation were linked to lower disease activity, better global
health, and more positive beliefs about their control over
the disease. A cross-sectional survey [13] with patients
diagnosed with inflammatory arthritis revealed that poor
communication (e.g. rushed consultations) and clini-
cians’ reluctance to ask about psychological and social
problems, left patients feeling unsupported. Conversely,
patients experienced less psychological distress when
clinicians helped them to adjust to their life with inflam-
matory arthritis.
Furthermore, a qualitative study [14] explored rheuma-
tology clinicians’ (including nurses) experiences of training
courses designed to facilitate patient self-management.
Clinicians appreciated explanations of the theory which
underpins self-management. All clinicians identified learn-
ing from the continuous professional development train-
ing which enhanced their clinical practice, such as the use
of tools and techniques to support patients’ behaviour
change. Clinicians found it challenging, however, not to
problem solve on behalf of their patients. Concerns in-
cluded how clinicians need to respond if complex psycho-
logical issues arose during a consultation. Patients who
attended routine consultations with the clinicians who
attended the training courses were interviewed [15]. They
appreciated the open, patient-centred, communication
style and clinicians’ understanding of the different ways in
which inflammatory arthritis affected them. Patients
seemed to be able to self-manage their long-term condi-
tion better when they were actively involved in their own
care.
Evidence therefore suggests that intensive management
may improve outcomes for patients with moderate RA.
The Treatment Intensities and Targets in Rheumatoid
Arthritis Therapy (TITRATE) trial seeks to examine
whether intensive management strategies improve out-
comes for patients with moderately active disease, defined
through achieving remission at 12months. Intensive man-
agement involves the combination of treatments including
DMARDs, steroids and sometimes biologics, together
with a ‘treatment support’ programme of non-drug inter-
ventions and psychosocial support [16]. The intensive
management intervention was delivered by rheumatology
practitioners (who were mostly nurses) across sites in
England, full details of the intervention are reported else-
where [16]. Briefly, the intensive management intervention
was a complex intervention [17] that consisted of several
interlinked components: 1) 12 x monthly appointments
with rheumatology practitioners for up to 1 h, 2) tailored
‘treatment support’ based on motivational interview tech-
niques [18], 3) increased medication according to an
agreed treatment algorithm, based on monthly disease ac-
tivity assessments (which included the opportunity to pre-
scribe biologics), 4) receipt of a Patient Handbook to
support intensive management (developed with patients
and clinicians) [19], and 5) a ‘shared treatment plan’ (de-
veloped with patients).
Qualitative studies which are nested in trials are uncom-
mon, however, they are useful to explore recipients’ and
providers’ responses to complex interventions [20]. This
study aims to understand: a) patients’ and practitioners’
views on the feasibility and acceptability of TITRATE in-
tensive management, and b) patients’ and practitioners’
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experience of receiving/providing TITRATE intensive
management.
Methods
This was a qualitative study nested within the TITRATE
trial [21]. We recruited patient and practitioners from 42
rheumatology outpatient clinics across England. There
were no additional patient inclusion or exclusion criteria
for this study to those of the trial [7] (see Additional file 1).
Practitioners were trained healthcare professionals,
who were often but not always nurses, identified by
the Principal Investigator as being competent to pro-
vide the intervention [16]. The inclusion criterion for
practitioners for this study were to have delivered at
least six intensive management sessions with the same
patient. The rationale for this criterion was to allow
healthcare professionals time to have applied the in-
tensive management strategies and techniques prior to
the semi-structured interview.
Recruitment
During their first intensive management session, practi-
tioners provided each patient with written information
about a ‘sub-study’ which included an optional
semi-structured interview. The invitation letter re-
quested that patients who chose to participate in the
sub-study should complete the consent form and return
the document directly to the lead researcher (LP).
Patients who chose to take part in the semi-structured
interview were asked to sign a second consent form.
Practitioners were sent an e-mail with a participant in-
formation sheet attached. Recruitment to the study was
stopped once there were no further themes emerging
from the data.
Data collection
The lead researcher (LP) developed the semi-structured
topic guides for patients and practitioners (see Add-
itional file 2). These were based on the five constituent
components of the intensive management intervention.
Questions focused on the acceptability and feasibility of the
intensive management intervention. The semi-structured
topic guides were discussed with the multi-disciplinary re-
search team and a departmental Patient Expert (SdS) who
provided feedback on the suitability and relevance of the
questions [22]. Topic guides were also reviewed by the two
other researchers (HL, JS).
The lead researcher (LP), who has experience of con-
ducting qualitative research and was not involved in the
direct care of any of the patients, carried out the
audio-recorded interviews between February 2016 and
September 2017. Individual interviews were conducted
with patients (n = 15) and practitioners (n = 13) [23],
both face-to-face (n = 8) and over the telephone (n = 20)
[24]. One focus group was also held with three practi-
tioners which used the same topic guide as the inter-
views. Interviews with patients were arranged for a date
after patients had completed all their intensive manage-
ment sessions, in case the interview influenced their
views about the trial intervention. No pilot interviews
were held; however, slight adjustments were made to the
topic guides following the first two interviews with each
group (e.g. the wording of the questions). Ethics ap-
proval for the patient sub-study was obtained from West
London & GTAC Research Ethics Committee (Reference:
13/LO/1308) on 3rd December 2014. The interviews with
the practitioners were considered a service evaluation;
therefore, a formal Research Ethics Committee approval
was not required.
Data analysis
Interviews were transcribed verbatim, by an external
professional agency, and coded shortly after completion
in order to inform when data saturation was reached. A
deductive approach to analysis was taken based on the
interview schedule [25]. The lead researcher (LP) ana-
lysed both sets of transcripts through thematic analysis
[26] and iterative categorization [27] (supported by
NVivo 10, a qualitative computer software programme).
Iterative categorization generates a clear audit trail with
the data analysis, closely linked to the raw data and in-
volves four stages: 1) familiarisation through the reading
of transcripts, 2) line by line coding to organise the data
in preparation for analysis, 3) descriptive analysis which
identifies themes, and 4) interpretive analysis that ex-
plores patterns, inconsistencies and relates findings to
existing knowledge.
To validate the data, a second experienced qualitative
researcher (HL) cross-referenced the emergent themes
with the lead researcher (LP), and consensus between
both researchers was reached. In addition the lead re-
searcher (LP) referred to the original transcripts
throughout the analysis, and deviant accounts were in-
cluded [28].
Results
Table 1 show the patient demographic information. Fif-
teen patients (12 females:3 males) from ten rheumatology
clinics consented to participate. Patients were all Cauca-
sian, with a mean age of 58 years (range 35–70 years old),
Table 2 shows the practitioner demographic informa-
tion. Sixteen practitioners (13 research nurses, 3 special-
ist nurses) from 13 rheumatology clinics consented to
participate. Practitioners were all female, with a mean
age of 49 years (range 30–70 years).
Based on constituent parts of the intensive manage-
ment intervention, 13 themes were identified (see
Table 3).
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Monthly Appointments
Monthly appointments acceptable
Patients did not mind attending the monthly intensive man-
agement sessions with the rheumatology practitioners. Facil-
itators to attend the appointments included patients being
retired and their healthcare professionals’ flexibility with the
proposed future monthly dates. The main enabler, however,
was that patients experienced that the sessions were valu-
able, because they were ‘getting something from them’. The
patients who were employed or had family commitments,
e.g. caring for an unwell relative, found the monthly
appointments demanding. Despite this, they were pleased to
have participated in the trial for the twelve-month duration.
‘With working full-time as well and having to go up there
[clinic appointments], it was difficult, because in work I
had to work my breaks to be able to make those appoint-
ments. So there was difficulty in getting there [clinic ap-
pointments], but I wanted to go.’ (10F55–64)
Thirteen of the practitioners were research nurses and,
in their roles, they come across different pressures.
Overall, practitioners successfully managed to see pa-
tients for monthly intensive management appointments.
Facilitators to successfully manage the monthly consulta-
tions were having enough time to space the appoint-
ments out and meeting motivated patients who were
keen to attend. Problems encountered were mainly logis-
tical (e.g. room availability in the clinic). Some commen-
ted that seeing patients every month would be more of a
challenge if multiple patients were attending intensive
management sessions.
‘I book the patient in knowing - I'm not booking them in
at 10 o'clock, knowing I've got another patient at 11. I
book a 10 o'clock slot with a possible other patient at 12
o'clock. So in that respect I'm fortunate.’ (9RN)
Access to services/consultant
One of the main advantages of monthly appointments
was increased access to services (e.g. physiotherapy, oc-
cupational therapy, neurology, x-rays, MRI scans). Any
concerns patients raised during the session, the practi-
tioner acted upon promptly. The additional contact with
the consultant rheumatologist (either directly or via
their rheumatology practitioner) and the opportunity to
receive a steroid injection straight away, were reported
as advantageous by patients and practitioners.
‘There were a few things [medical concerns] I
mentioned and immediately the consultant said
“Right, well we'll have an MRI scan on that, we'll have
x-rays on it”. It was really good stuff.’ (4M65+)
Monthly appointments beneficial
Patients and practitioners found the monthly appoint-
ments helpful as medication could be reviewed more
regularly, treatment could be changed faster to control
the disease, and regular appointments were a ‘reassur-
ance’ to patients if a problem occurred (e.g. side-effects
from medication). Monthly appointments allowed for
regular blood monitoring.
Table 1 Patient demographic information
Number Gender Age range (years) Self-reported ethnicity Site
1 Female 65+ White British A
2 Female 55–64 White British A
3 Female 55–64 White British A
4 Male 65+ White British B
5 Female 65+ White British B
6 Female 45–54 White Caucasian B
7 Female 55–64 White British C
8 Male 35–44 European White C
9 Female 65+ White British D
10 Female 55–64 White British E
11 Female 65+ White British F
12 Male 35–44 European White G
13 Female 65+ White British H
14 Female 55–64 White British I
15 Female 35–44 White British J
Table 2 Practitioner demographic information
Number Role Site
1 Research nurse A
2 Research nurse A
3 Specialist nurse A
4 Research nurse B
5 Research nurse B
6 Specialist nurse C
7 Research nurse D
8 Research nurse E
9 Research nurse F
10 Specialist nurse G
11 Research nurse H
12 Research nurse I
13 Research nurse J
14 Research nurse K
15 Research nurse L
16 Research nurse M
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‘If they decided that I needed a change in medication
or increased the medication [ … ] they [practitioners] were
closely monitoring it [patient’s response to medication]. It's
like fine-tuning an engine really. That's how I equate with
it [process of medication titration].’ (4M65+)
Patients appreciated the additional time with the prac-
titioner and reported feeling ‘safe’ and ‘looked after’.
They described professionals as someone to talk to
about their emotional state, with whom they could dis-
cuss ideas with and ask for advice.
‘I found them [sessions] very, very useful definitely. It
[attending the sessions] was extremely good in helping
me to go forward, understand what was happening
with my body, having everything checked out properly,
not feeling that you were on your own in a dark
tunnel.’ (2F55–64)
Healthcare professionals enjoyed meeting regularly for
the intensive management sessions ‘to establish a proper
relationship’, ‘build rapport’ and ‘really get to know’ their
patients. They recognised that patients appreciated their
support.
‘I think it's also helpful because prior to them [the
patient] coming into the study you don't know the
patient so you're building up that rapport all the time
and by seeing them more regularly.’ (9RN)
Intensive management preferable to standard care
Those interviewed either saw their consultant annually,
every 6 months, or every 3 months under standard care [7].
Problems conveyed because of the infrequent appointments
included patients not seeing the consultant when their RA
was at its worst and them finding it difficult to recall how
they had felt physically since their previous appointment.
Consultations were described as ‘rushed’ with little time for
discussion.
‘[ … ] and then you go once a year but you just feel
like a number. This is this, this is this, okay, how is it
[RA]? Fine. We'll see you in another 12 months and
you're just left like oh my God.’ (15F35–44)
Practitioners reported routine appointments as too
medically focused, with a limited time to discuss change
of lifestyle factors. Due to seeing more patients for shorter
appointments, they tended to review patients and check
their disease activity only. Several interviewees mentioned
they prefer the care patients receive in the intensive man-
agement arm and think it is unfortunate there is not the
time to deliver the same level of care in standard practice.
‘If you've got a clinic of seven [patients booked], you've
got to churn them through [ … ] the nurse being a
pastoral carer has gone. We're basically following up
and checking their disease activity scores and things
like that now [ … ] Whilst you get that pastoral care
with the TITRATE and they [patients] see it [pastoral
care], they love it.’ (1RN)
The Therapeutic Relationship
Practitioners ‘fairly’ confident using motivational
interviewing techniques
Practitioners’ confidence to deliver the motivational
interviewing techniques varied between individuals,
however, most described themselves as ‘fairly confident’.
They explained how the techniques seemed to be diffi-
cult at the beginning of the application but became eas-
ier with practice. Some practiced the motivational
interviewing techniques during standard care appoint-
ments. Facilitators to delivery included to meet several
intensive management patients close together, who
responded and progressed well, and previous experience
of delivering psychoeducational interventions.
‘I think that they [the sessions] become easier as the
sessions develop. I think just that first two or three
[sessions] when you don’t really know each other and
you’re trying to encourage that - to encourage the
conversation more than just a yes or a no, it’s quite
difficult.’ (7RN)
Table 3 Constituent components of the intensive management
intervention and identified themes
Components of the intensive
management intervention
Themes
1. Monthly Appointments Monthly appointments acceptable
Access to services/consultant
Monthly appointments beneficial




Practitioners ‘fairly’ confident using
motivational interviewing techniques
Patients and practitioners work on
goals together
Importance of continuity of care
Provision of helpful information
3. Increased Medication Improvement in RA symptoms
Side-effects of medication
Treatment algorithm easy for
practitioners to use
4. Patient Handbook Views on the content of the Handbook
Introductory use of Handbook
5. Shared Treatment Plan Views on the shared treatment
planning
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‘I'm probably fairly confident because I've done this
counselling course in the past.’ (5RN)
Several interviewees explained the difficulty to change
their communication style towards a patient-centred ap-
proach. Reasons provided were that they had ‘spent so long
doing consultations a certain way’ and the newly acquired
approach being different. Specific challenges reported by
practitioners included the use of open-ended questions, let-
ting patients talk, and not telling patients what to do.
‘That's the bit that I find really hard with
motivational interviewing, because they've [patient]
probably got about a 10 second span to answer that
question, if they [patient] don't, I'm going to fill it in
[answer the question] for them.’ (1RN)
‘I think that's the thing [motivational interviewing
technique] I find the most difficult, is trying to do it
[ask a question] in a way that it is an open question,
rather than just a yes or no answer.’ (10SN)
Patients and practitioners worked on goals together
Weight loss (either through a change in diet or in-
creased physical activity) and exercise were the most
commonly reported goals by patient. Other areas of
support included management of fatigue, pain, and
regulation of sleep patterns. Patients described how
they identified these with their practitioner, who
‘helped to organise them’ and ‘gently encouraged
them’ to introduce changes. Practitioners’ monitoring
progress at subsequent intensive management sessions
was described as helpful, as was having someone to
go back to when a plan had not worked, or when
they had an idea which they needed to discuss.
‘I think the combination, the diet with the medicine,
it's given me a good effect.’ (12M35–44)
‘A couple of the aims and goals I had, like reducing
alcohol and doing more exercise, I did do. So it was
useful talking to somebody every month.’ (13F65+)
Learning to self-manage was an important part of the
intensive management sessions. Most patients discussed
strategies they used to ‘pace’ their activities so as not to
get fatigued. These included to break tasks down into
smaller parts, recognise when a job is beyond their cap-
ability, listen to their body rather than ‘push through’,
and not become angry when they cannot do everything
they want to. One patient participant reported that the
intensive management sessions had changed little about
the way she manages her RA.
‘She [rheumatology practitioner] said try not to do
everything all at once [ … ] Daft things like say
painting the bedroom, I could have done that in one
day at one time, but it's taking us three days now, but
it's done.’ (14F55–64)
‘I've got to admit I can't really say it has had a lot of
impact on my management of it [RA]’ (10F55–64)
Many healthcare professionals reported that the inten-
sive management sessions had a positive impact on pa-
tients’ self-management. Self-management support was
less helpful to patients who were already motivated and
able to self-manage.
‘It's a difficult one to gauge because the two patients
that are in the intensive management arm are fairly
motivated individuals anyway.’ (16RN)
Practitioners explained how the treatment support had
helped some patients to become more self-aware and in-
creased patients’ knowledge of how best to help them-
selves (e.g. self-management strategies for coping with
pain) which resulted in them taking control of their
long-term condition.
‘It’s looking at the bigger picture of what else you can
do. It might be that the pain has flared up because
they’re [patient] sitting in a chair all day. Or is their
mood affected because they’re isolated at home
because they’re not able to get out and about?’ (7RN)
Importance of continuity of care
Continuity of care was very important to patients be-
cause they could see a practitioner who was already fa-
miliar with their medical history/joints, and not have to
repeat the same information to a new clinician every
visit. Emotional benefits included the participant and
practitioner ‘getting to know’ each other. This continuity
meant that the patient felt ‘comfortable’ and developed
trust and a bond with the practitioner.
‘After a while once I got to know them [practitioners]
we got on a lot better. I was less embarrassed I
suppose is the word or maybe less reserved. I was able
to talk to them [practitioners] about anything really. I
suppose it's building up trust isn’t it?’ (10F55–64)
Provision of helpful information
Most patients said that their practitioner helped them to
learn about RA and understand the condition more.
Knowledge about RA and its treatments, and what to
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expect from these, is something patients found valuable.
Areas mentioned specifically by patients included fa-
tigue, pain, medication management and the difference
between RA and osteoarthritis.
‘You know I'm just feeling pretty good, because my
nurse helped me to understand my illness and she
explained clearly how it [the medication] works, what
I can expect, and that was a very good experience for
me.’ (12M35–44)
Increased Medication
Improvement in RA symptoms
Most patients found the change in medication, including
the use of biologic therapies, helpful. They reported that
their RA had improved, and that the symptoms were more
controlled. Patients described the impact of this improve-
ment (e.g. improved dexterity, increased physical activity,
better self-confidence, return to employment). Steroid injec-
tions were regarded as particularly effective for the fast relief
of localised pain. A small number of patients felt less satis-
fied with their treatment e.g. because it was not as effective
as their previous medication, and continuous symptoms of
RA (such as fatigue and pain). One participant was pre-
vented from starting biologic treatment due to an infection.
‘I've had arthritis for 34, 35 years [ … ] and only just
recently I feel that it's [RA] finally been controlled [ …
] I've got stiff swollen joints that have been damaged,
they'll never be repaired I know that, but the fact that
I'm not having flare after flare after flare, which I was
having that's a great relief to me.’ (1F65+)
‘Unfortunately, the first one [drug] they put me on just
hasn't worked. I've been having very severe ‘flare ups’ of
arthritis. I'm on another one [medication], a biologic
now, but unfortunately I've had several infections
which haven't allowed me to take it.’ (13F65+)
Side-effects of medication
About half of patients experienced no side-effects during
the intensive management intervention. Side-effects encoun-
tered by others in the group included steroid-induced
weight gain, rash, hair loss and nausea. These were mainly
occurred after an alteration of their medication. Most re-
ported that the side-effects subsided or improved with time
or the clinician discontinued or modified the drug that
caused the side-effect. Nobody reported problems in relation
to changes of drug administration (e.g. self-injection) or the
delivery of drugs to their home.
‘At first, I found it very hard, because I was just taking
medicines and medicines. I had a few little side-effects
- upset stomach and feeling a bit down and drowsy.
But overall when I got through the first few weeks, fine.’
(2F55–64)
Treatment algorithm easy for practitioners to use
Practitioners described the treatment algorithm as clear
and easy to follow. They stated that the pathway with
regards to drug treatment was close to standard care.
Research practitioners, who are unable to prescribe,
would seek the advice of the consultant before they al-
tered treatment. Some commented that relying on the
consultants’ decision was a barrier to the sessions.
Others enjoyed the opportunity to learn more about RA
medications. Practitioners liked the option to offer bio-
logics to patients with moderate RA, which would not
be allowed in routine practice.
‘The rest of the intensive management stuff I'm
absolutely happy with. It's the changes in medication,
where I have to rely on other people, to do
prescriptions and things like that that I think held me
back.’ (12RN)
Patient Handbook
Views on the content of the handbook
Most patients described the Handbook as ‘useful’, ‘in-
formative’, ‘interesting’ or as ‘a good introduction to the
trial’. Some patients, however, did not find the Hand-
book beneficial. Reasons cited included the content was
irrelevant to them, the Handbook presented information
in a negative way, and they already knew a lot of the in-
formation presented in the document (e.g. to establish a
regular sleep pattern, eat five portions of fruit and vege-
tables per day). Feedback about the activity form and ac-
tion plans included in the Patient Handbook was also
mixed. One person commented that it was more con-
venient to use the diary on his mobile phone as an activ-
ity record rather than writing on the paper copies.
‘Oh yeah [ … ] it [handbook] was very informative you
know, like loads of information and lots of help.’
(14F55–64)
‘A lot of it [content of the handbook] wasn't relevant to
me.’ (4M65+)
Feedback from practitioners about the content of the
Handbook was very positive. They described the re-
source as ‘comprehensive’, ‘useful’, ‘clearly written’ and
one which patients in the intensive management arm of
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the trial were pleased to read in their own time. The
Handbook provided an important asset for healthcare
professionals to refer patients to for help with difficulties
such as fatigue and exercise.
‘I do refer patients back to the information in the
handbook when they're, for example, struggling with
fatigue or exercise [ … ] I've also given the handbook
out or I've shown other practitioners the handbook
because it's a great resource.’ (6SN)
Practitioners utilized the Health Behaviour Check
form, Balance Sheets, and Activity Diaries in the back
of the Handbook as part of the motivational inter-
viewing approach. They suggested to keep these
sheets separate from the rest of the Handbook. In
addition, they suggested that the pages could go into
a smaller booklet which could be transported more
easily and discreetly than the Handbook.
Introductory use of the handbook
Despite the mainly positive feedback from most patients
about the Handbook, one interviewee did not use the re-
source and over half admitted that they read the docu-
ment only at the start of the trial.
‘I can't say I used it [handbook] often, but I did use
it [ … ] I did use it to begin with more than I did
at the end.’ (10F55–64)
Practitioners described two categories of patient: one
who would read the Handbook carefully and bring the re-
source to the sessions, and others who did not show much
interest in the material. Although some stated that the pa-
tients made use of the resource, the majority explained that
patients did not bring the document to their sessions. Prac-
titioners found it, therefore, difficult to engage with patients
who were less keen on the content.
‘We've got those that want to read everything and then
you get those that don't want to know anything, just
give me a new tablet [pill] and I'll start it.’ (3SN)
Shared Treatment Plan
Views on the shared treatment planning
Several patients forgot to complete the Shared Treatment
Plan with their practitioner. Those who remembered de-
scribed the Shared Treatment Plan as ‘interesting’, ‘good
and comprehensive’ and the process of shared completion
as ‘useful’. A few patients thought drafting the Shared
Treatment Plan facilitated collaboration between them-
selves and their practitioner at the start of the trial.
It [the process of completion] was useful for me to sit
down and put it [previous medication, medication
preferences] in black and white. I suppose it [the
process of completion] was good for him to find out
where my head was at.’ (15F35–44)
Feedback from health care professionals about the
Shared Treatment Plan was mixed. Out of those who
had completed it, some explained that this process was
already standard practice. Others fed back that they had
completed the document but did not refer to the plan in
later sessions. Positive comments about the shared treat-
ment plan from practitioners revealed that the Plan was
helpful when ‘getting to know’ a patient and ‘triggered
discussion and more questions’. In addition, they ex-
plained in future negotiations about patients’ preference
(e.g. unlikely to take steroids) the document was benefi-
cial. Similar to the goal-setting forms, practitioners re-
ported that the Shared Treatment Plan needs to be
separate from the Handbook.
‘Yes [ … ] I have found that [the Shared Treatment
Plan] useful but [ … ] I'll be honest I haven't really
referred back to it very often. I don't know if that's just
a fault of mine or whether it's because the sessions
have taken their own path.’ (13RN)
Discussion
Main findings
Consistent with previous research [9] the intensity of
monthly appointment intervals over 12 months was ac-
ceptable and highly valued by the majority of patients,
and also by the practitioners who delivered the intensive
management intervention. Practitioners were reasonably
confident with the use of motivational interviewing tech-
niques. As observed in previous studies [14, 29] some
described difficulty with altering their established con-
sultation style. Learning to pace was the most commonly
reported self-management technique which patients and
practitioners worked on together, followed by gaining
control over pain and fatigue. Patients appreciated the
verbal encouragement they received from their practi-
tioner. Consultation with the same healthcare profes-
sional for each session had both physical and emotional
benefits for patients. Treatment support was helpful for
patients who required guidance on how to manage the
disease and increased some patients’ self-awareness and
sense of control over their symptoms. Practitioners liked
the option to offer patients with moderate RA biologics.
Most patients found the increased medication helpful,
and side-effects experienced by participants were re-
solved in time. Variation existed in the degree to which
patients engaged with the Patient Handbook and
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Shared Treatment Plan [9, 10]. Both practitioners and
patient participants reported a key advantage of the
monthly consultations was to acquire more knowledge
about their RA and discuss its management.
Findings compared to wider literature
Patients with RA live with complex symptoms, such
as fatigue and pain, which can have emotional, cogni-
tive and behavioural impacts [30]. It is useful to com-
pare our intensive management intervention with
those across other diseases, which aim to improve
complex symptoms. The British Pain Society has pub-
lished guidelines for interdisciplinary pain manage-
ment programmes (PMPs) [31]. Unlike the intensive
management intervention PMPs are based on cogni-
tive behavioural principles. There are three different
types of programmes: targeted early PMP interven-
tions, standard PMPs (12 x half day sessions), and in-
tensive PMPs (e.g. 15–20 full days). The programmes
include education, guided practice on exercise and ac-
tivity management, goal-setting, identifying and chan-
ging unhelpful beliefs and ways of thinking, relaxation
and changing habits which contribute to disability.
Compared with no treatment or treatment as usual,
there is evidence PMPs improve pain experience,
mood, coping, negative outlook on pain and activity
levels [26]. Qualitative findings from our study high-
light that intensive management in RA improved
weight loss, exercise, control over pain, and pacing.
Therefore, the outcomes are similar to PMPs. It is recom-
mended that self-management principles are introduced
early in the pain experience. Early intervention directed at
high-risk patients has been shown to be both clinically
and cost-effective [30].
For fatigue, physical activity and psychosocial inter-
ventions are effective for patients with RA [32]. Mod-
erate physical activity is also recommended to
improve cancer-related fatigue as are pharmacological
approaches, adjustment strategies (e.g. prioritizing ac-
tivities, managing stress and anxiety), complementary
therapies, and psychological and educational interven-
tions [33]. A review of educational interventions for
the management of cancer-related fatigue in adults
showed they may have a small effect on reducing fa-
tigue (its intensity, interference with daily life, gen-
eral/overall fatigue) and could have a moderate effect
on decreasing fatigue distress [34]. Due to the com-
plexity of this symptom, the review authors concluded
that educational intervention would result in greater
reductions in fatigue when employed in conjunction
with other interventions [34]. This supports the com-
plex design of our intensive management intervention,
which utilizes educational materials, plus pharmaco-
logical and psychosocial intervention.
Strengths and limitations
This study has provided detailed insight into patients’
and practitioners’ views of the intensive management
intervention within the context of a pragmatic trial. As
far as we are aware, this is the first qualitative study to
evaluate the experiences of patients with moderate RA
that receive intensive management. Recruitment of pa-
tient and practitioner participants from a total of 18/42
diverse geographical sites across England was a strength
as the experiences of clinicians and patients from differ-
ent clinics were evaluated [35].
Limitations of the study include the use of a poten-
tially biased sample. Both practitioners and patients
volunteered to take part in the interviews. It is possible
that those who engaged more with the delivery or re-
ceipt of the intensive management intervention would
be keener to participate. Patients were largely elderly, re-
tired, and all Caucasian, therefore, not representative of
the RA population. Practitioners were mostly research
nurses (13/16). Research nurses face different barriers
compared to specialist nurses (e.g. relying on consultants
to change patients’ medication, less experience of regu-
larly seeing patients with RA). Feedback from practi-
tioners in relation to the intensive management
intervention may have been different from clinicians de-
livering standard care. The ratio of research nurses to
specialist nurses in the interviews was, however, broadly
proportional to the number of research nurses/specialist
nurses who delivered the intensive management sessions
in the trial.
Recommendations for future research
Overall, the intensive management intervention was ac-
ceptable to patients, whose feedback was positive. Partic-
ipants found the increased medication helpful, however,
seeing the same practitioner at regular intensive man-
agement sessions, and the treatment support they pro-
vided, were equally as significant.
There is evidence from these interviews that practi-
tioners would like the opportunity to address lifestyle is-
sues with patients in routine appointments. The
restricted length and frequency of standard care appoint-
ments is an important limitation to quality care
provision. Some practitioners did, however, report using
the motivational interviewing techniques with patients
they see in the standard care pathway. This suggests
practitioners were able to transfer some of the skills they
learned during the training and use them in time-limited
appointments. Feedback from practitioners also indicates
that intensive management training is feasible. Future
research could examine the most practical and
cost-effective way to deliver both this teaching to practi-
tioners, and, the intensive management components to
patients with moderate RA in standard care.
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Conclusions
Both patients’ and practitioners’ feedback about the
feasibility and acceptability of the intensive management
intervention was positive. Patients found the increased
medication and support from the practitioner helpful.
Practitioners enjoyed taking a more holistic approach,
which was facilitated by the longer sessions. These find-
ings indicate that patients with RA would like more con-
tinuity of care and support with symptom management.
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